Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 7, 2012, Pages 536-540

  Zaghloul, Hanna A ^a   Murillo, Jose R ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

castrate resistant; end of life; hospice; palliative care; prostate cancer; treatment

Indexed keywords

EID: 84867715322     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111433128     Document Type: Article

References (22)

1. Siegal R,Ward E,Brawley O,Jemal A.Cancer statistics, 2011.CA Cancer J Clin. 2011;61 (4): 212-236.
2. Stavridi F,Karapanagiotou EM,Syrigos KN.Targeted therapeutic approaches for hormone-refractory prostate cancer.Cancer Treat Rev. 2010;36 (2): 122-130.
3. Hwang SS,Chang VT,Alejoandro Y, et al.Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center.Cancer Invest. 2004;22 (6): 849-857.
4. Petrylak DP,Tangen CM,Hussain MH, et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med. 2004;351 (15): 1513-1520.
5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004;351 (15): 1502-1512.
6. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial.Lancet. 2010;367:1147-1154.
7. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med. 2010;363:411-422.
8. Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med. 2011;364 (21): 1995-2005.
9. Fitzpatrick JM,Anderson J,Sternberg CN, et al.Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.Crit Rev Oncol Hematol. 2008;68 (suppl 1): S9-S22.
10. Mitchell RE,Change SS.Current controversies in the treatment of high-risk prostate cancer.Curr Opin Urol. 2008;18 (3): 263-268.
11. Lin AM,Small EJ.Management of hormone refractory prostate cancer.Curr Opin Support Palliat Care. 2007;1 (3): 187-191.
12. Earle CC,Neville BA,Landrum MB, et al.Trends in the aggressiveness of cancer care near the end of life.J Clin Oncol. 2004;22 (2): 315-321.
13. Earle CC,Landrum MB,Souza JM, et al.Aggressivess of cancer care near the end of life: is it a quality-of-care issue?.J Clin Oncol. 2008;26 (23): 2860-2866.
14. Murillo JR,Koeller J.Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer.The Oncologist. 2006;11 (10): 1095-1099.
15. Bergman J,Saigal CS,Lorenz KA,Hanley J,Miller DC,Gore JL,Litwin MS.Hospice use and high-intensity care in men dying of prostate cancer.Arch Intern Med. 2011;171 (3): 204-210.
16. Ho TH,Barbera L,Saskin R,Lu H,Neville BA,Earle CC.Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada.J Clin Oncol. 2011;29 (12): 1587-1591.
17. Lyman GH,Kuderer NM,Balducci L.Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.Curr Opin Oncol. 1998;10 (4): 291-296.
18. Lyman GH,Kuderer NM.The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.Crit Rev Oncol Hematol. 2004;50 (2): 129-146.
19. Burke TA,Wisniewski T,Ernst FR.Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.Support Care Cancer. 2011;19 (1): 131-140.
20. Craver C,Gayle J,Balu S,Buchner D.Clinical and economic burden of chemotherapy-induced nausea vomiting among patients with cancer in a hospital outpatient setting in the United States.J Med Econ. 2011;14 (1): 87-98.
21. Bergman J,Chi AC,Litwin MS.Quality of end-of-life care in low-income, uninsured men dying of prostate cancer.Cancer. 2010;116 (9): 2126-2131.
22. Cancer care during the last phase of life.J Clin Oncol. 1998;16 (5): 1986-1996.